Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Change in weight (kg) · People who have quit smoking
Nicotine replacement therapy for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (moderate certainty).
3 findings from 1 review
MD 0.52
21 studies · 2784 participants
Moderate
MD 0.08
11 studies · 1021 participants
Moderate
MD 0.37
17 studies · 1463 participants
Moderate
Change in weight (kg) · People who have quit smoking
Varenicline for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (high certainty).
3 findings from 1 review
MD 0.23
14 studies · 2566 participants
High
MD 0.09
3 studies · 384 participants
Low
MD 1.05
3 studies · 237 participants
Low
Change in weight (kg) · People who have quit smoking
Fluoexetine showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (low certainty).
2 findings from 1 review
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (6 weeks' · primary Raynaud's phenomenon
Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found